The guidance raise and beat confirm underlying demand momentum in hips and the Technology & Data segment. However, with 22 Hold ratings and a prior neutral reaction to a similar beat, the upside may be capped. Monitor the earnings call for details on the ROSA Shoulder System launch and the go-to-market transformation timeline.
Price Chart
Executive Summary
Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07, a 3.0% beat vs. consensus of $2.01, on revenue of $2.177B (above $2.14B consensus). Revenue grew 4.8% reported (4.0% organic constant currency). The company raised full-year 2026 guidance: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%) and adjusted EPS to $8.47-$8.59 (from $8.40-$8.55), signaling confidence in H2 momentum. The beat and guidance raise are positive, but the magnitude is modest for a large-cap medtech, and the prior quarter's cross-filing context showed a similar beat with a neutral market reaction, suggesting limited upside surprise.
Key Financial Metrics
Key Facts
- Q2 2026 net sales of $2.177B, up 4.8% reported and 4.0% organic constant currency YoY
- Adjusted diluted EPS of $2.07, beating consensus of $2.01 by 3.0%
- Full-year 2026 guidance raised: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%), adjusted EPS to $8.47-$8.59 (from $8.40-$8.55)
- Operating cash flow of $447.9M and free cash flow of $308.3M in Q2
- Share repurchase expectations increased to up to $1 billion for FY 2026
Financial Impact
Q2 revenue $2.177B vs $2.14B consensus; adjusted EPS $2.07 vs $2.01 consensus; FY guidance raised by ~$0.10 at midpoint
Risk Factors
- Knee segment growth decelerated to 0.4% reported (0.1% constant currency), signaling competitive or market share pressure
- Restructuring charges of $29.8M and litigation charges of $12.3M weighed on GAAP results
- Net debt increased to $7.069B from $6.927B at year-end, partly due to $500.8M in share repurchases
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333761 |
| Document: zbh-20260805.htm | 0001193125-26-333761 |
| Document: 0001193125-26-333761-index-headers.html | 0001193125-26-333761 |
| Document: 0001193125-26-333761-index.html | 0001193125-26-333761 |
| Document: 0001193125-26-333761.txt | 0001193125-26-333761 |
| 8-K Data (Synthetic) | 0001193125-26-333761 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $98.41 $93.98 | ▼ −4.50% | ▼ −6.63% | $87.94 (−10.64%) |
Sep 2, 2026 4w ago | Court Ruling | $99.50 $92.44 | ▼ −7.10% | ▼ −6.14% | $87.94 (−11.62%) |
Aug 17, 2026 6w ago | Court Ruling | $98.20 $100.98 | ▲ +2.83% | ▲ +4.02% | $87.94 (−10.45%) |
Aug 5, 2026 8w ago | 8-K | $98.16 $97.89 | ▼ −0.28% | ▼ −0.63% | $87.94 (−10.41%) |
May 12, 2026 20w ago | 8-K | $83.34 $85.14 | ▲ +2.16% | ▲ +2.09% | $87.94 (+5.52%) |
May 1, 2026 22w ago | Court Ruling | $82.86 $83.37 | ▲ +0.62% | ▼ −1.73% | $87.94 (+6.14%) |
Apr 28, 2026 22w ago | 8-K | $82.45 $82.63 | ▲ +0.22% | ▼ −1.47% | $87.94 (+6.66%) |
Apr 28, 2026 22w ago | 8-K | $82.45 $82.63 | ▲ +0.22% | ▼ −1.47% | $87.94 (+6.66%) |
Apr 1, 2026 26w ago | DEFA14A | $91.00 $93.03 | ▲ +2.24% | ▼ −1.53% | $87.94 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access